CellCarta
ActiveSummary
CellCarta has been active since 2001 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €25.9m and a net result of €7.7m. Equity has been growing by about 20% per year since 2018. Its solvency ranks better than 43% of 239 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 23-04-2001 Normal situation
- Activity
- Other research and development on natural sciences NACE 72109and 1 other
- Joint committee
- 330.04 Paritair Comité voor de gezondheidsinrichtingen en -diensten · annual accounts 2025
- Establishment units
- 2.116.346.295 2610 Antwerpen, since 11-06-2001
- 2.381.109.082 2610 Antwerpen, since 01-01-2023and 1 other
- Financial year end
- 31 December
- Peppol
- Reachable since 14-10-2025
Board and ownership
Board
- Kristien VerhoevenDaily manager
- Joshua SchultzDirector · since 06-02-2025
- Elliott MillerDirector
- Auditor
- Roel Boons BV
Shareholders
- HistoGeneX Holding83.3%annual accounts 2025
- Arsenal IO Canada 3consolidatesannual accounts 2025
- Holdings
- Shares in 2 companies CellCarta China Ltd and PATHOMATION
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
Annual accounts 2025
- Turnover
- €79.9m
- ▲ 7.9%
- Profit
- €7.7m
- ▼ 12.5%
- Equity
- €25.9m
- ▲ 42.4%
- Total assets
- €60.5m
- ▲ 4.5%
- Employees on 31-12-2025
- 260
- ▲ 1.6%
Score breakdownraises risk1 of the last 3 accounts latelowers riskSize: turnover €79.9m, 242.7 FTE, total assets €60.5mFounded in 2001Liquidity: current ratio 2.37, cash €7.3m, halvedShow the evidence
Checked score
Score 2025
96
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 71% of medium-sized companies in research and development (NACE 72)
Financial strength · tick: 2024
Strong
Solvency
68+12
equity 42.8% of total assets
Liquidity
50-12
short-term debt 33.7% · cash 12.1%
Profitability
87-1
return on assets 12.7%
Bankruptcy probability within 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.2%▲ +0.1 percentage points vs 07-2025
09-2025: 0.2%● unchanged vs 08-2025
10-2025: 0.3%▲ +0.1 percentage points vs 09-2025highest value
11-2025: 0.1%▼ -0.2 percentage points vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.1%● unchanged vs 06-2026lowest value
08-2026: 0.1%● unchanged vs 07-2026lowest value
09-2026: 0.1%● unchanged vs 08-2026lowest value
10-2026: 0.1%● unchanged vs 09-2026lowest value
11-2026: 0.1%● unchanged vs 10-2026lowest value
Credit of up to €2,450,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 2.37 (1.88 in 2024), above the usual 1.5. Short-term debt is 33.7% and cash 12.1% of total assets. However, 57.2% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, medium-sized). It does better than 49% of them on solvency, 57% on liquidity, 89% on profitability and 89% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 09-06-2026, 52 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
52 days early
2024
56 days late
2023
33 days early
2022
31 days late
2021
41 days early
2020
65 days early
2019
15 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 17 days before the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 June (4 of the last 5 accounts filed within 63 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
03-11-2026 today31-12-2026 year end31-07-2027 deadline
Key points
- Positive: Higher net result than 94% of companies in research and developmentsector median €3,198 · 237 companies €7.7m View
- Positive: 7 years of growth in a rowturnover 2025: €79.9m 7 years View
- Positive: Equity rose in 2025from €18.2m to €25.9m ▲ 42.4% View
- A director leftlatest change 11-03-2026 · 5 in office 1 left View
- Flemish supportawarded from 2022 to 2025 €235,088 View
Recent changes
- · Gazette deed Resignations: KOCKX-CONSULTING BV, Maurice Tenney III and PwC Bedrijfsrevisoren BVPermanent representatives: Mark Kockx and Roel Boons · Reappointments: PwC Bedrijfsrevisoren BV (statutory auditor) and Maurice Tenney III (director) · Appointment: Roel Boons BV (statutory auditor)
- · Gazette deed Reappointments: Kockx-Consulting BV (director) and Hendriks Consulting Company BV (director)Permanent representatives: Mark Kockx and Dirk Hendriks · Resignation: Anthony Mattacchione (director) · Appointment: Elliott Miller (director)
- · Gazette deed Resignation: David Spaight (director)Appointment: Joshua Schultz (director) · Permanent representatives: Dirk Hendriks and Mark Kockx
Companies linked to CellCarta
Comparable companies
These companies have the same main activity as CellCarta: other research and development on natural sciences (NACE 72109). They are comparable in size and age: total assets between €36m and €117m, founded between 1989 and 2005.
| Company | Total assets | Turnover |
|---|---|---|
| CellCarta Antwerpen | €60.5m | €79.9m |
| LabCorp Mechelen | €36.1m | €64.2m |
| HENOGEN Charleroi | €97.2m | €48.7m |
| Cargill R&D Centre Europe Vilvoorde | €99.2m | €62.7m |
| INEOS SERVICES BELGIUM Brussel | €63.4m | €46.7m |
| Clinigen Clinical Supplies Management Mont-Saint-Guibert | €44.9m | €56.8m |
| TotalEnergies OneTech Belgium Seneffe | €116.7m | €96.0m |
Key facts about CellCarta
- What is the company number of CellCarta?
- The company number of CellCarta is 0474.654.355. The VAT number is the same number with BE in front: BE 0474.654.355.
- Where is CellCarta based?
- The registered office is at Sint-Bavostraat 78, 2610 Antwerpen.Company details
- What does CellCarta do?
- According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
- What is the legal form of CellCarta?
- The legal form of CellCarta is Public limited company (NV).
- When was CellCarta founded?
- CellCarta was founded on 23-04-2001.
- Is CellCarta still active?
- Yes, CellCarta is an active enterprise in the KBO register.
- How many employees does CellCarta have?
- CellCarta had an average of 242.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does CellCarta fall under?
- In its 2025 annual accounts, CellCarta states joint committee 330.04 (Paritair Comité voor de gezondheidsinrichtingen en -diensten).
- What is the turnover of CellCarta?
- The turnover of CellCarta was €79.9m in financial year 2025, according to the filed annual accounts.
- Is CellCarta profitable?
- In financial year 2025, CellCarta made a profit of €7.7m.
- Where can I find the annual accounts of CellCarta?
- CellCarta filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CellCarta due?
- CellCarta must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.